Current session 09/06/2008

Query/Command : ..ba pluspat;
(us6689373)/PN /XPN

ER 5
You have typed an incorrect answer : please check the wording
of your response.
Continue the search in Questel.Orbit: Y / N

Query/Command : n

..FILE / ..INFO / ..GUIDE

?

Query/Command : ..ba pluspat;
(us6689373)/PN /XPN

QUESTEL - Time in minutes : 1,40
The cost estimation below is based on Questel's
standard price list
Estimated cost : 1.68 USD
Cost estimated for the last database search : 1.68 USD
Estimated total session cost : 1.68 USD

Selected file: PLUSPAT

PLUSPAT - (c) Questel, All Rights Reserved.
RELOADED 02/2008 Comprehensive Worldwide Patents database
Individual records for each Country or Patent Office
Coverage: 78 patenting authorities; start dates vary from 1800 forward
Abstracts/Titles in English, French & German. Increased standardization
of Assignee/Inventor names. Added cited ref's BE,CH,NL,TR,AU,& JPB
For PlusPat Fact Sheet, Pricing and FAQ, see the Questel website
Last update of file: 2008/06/06 (YYYY/MM/DD) 2008-23/UP (last update)

** SS 1: Results 1

Search statement 2

1 / 1 PLUSPAT - ©Questel - image
Patent Number :
  US2003171401 A1 20030911 [US20030171401]
Patent Number 2 :
  US6689373 B2 20040210 [US6689373]
Title :
  (A1) Devices and methods for pain management
Patent Assignee :
  (B2) DURECT CORP (US)
Patent Assignee :
  Durect Corporation, Cupertino CA [US]
Patent Assignee 2 :
  (B2) DURECT CORP (US)
Inventor(s) :
  (A1) JOHNSON RANDOLPH MELLUS (US); THEEUWES FELIX (US)
Application Nbr :
  US30672702 20021126 [2002US-0306727]
Filing Details :
  Cont. of US09522535 20000310 [2000US-0522535]
  Prov. AP US60125589 19990318 [1999US-P125589]
  Continuation of: US6541021
Priority Details :
  US30672702 20021126 [2002US-0306727]
  US52253500 20000310 [2000US-0522535]
  US12558999P 19990318 [1999US-P125589]
Intl Patent Class :
  (A1) A61K-009/22 A61K-031/445
IPC Advanced All :
  A61K-009/00 [2006-01 A - I R M EP]; A61K-009/22 [2006-01 A - I R M US];
  A61K-031/4468 [2006-01 A - I R M EP]; A61K-031/4535 [2006-01 A - I R M
  EP]; A61K-047/10 [2006-01 A - I R M EP]; A61K-047/14 [2006-01 A - I R
  M EP]; A61K-047/26 [2006-01 A - I R M EP]
IPC Core All :
  A61K-009/00 [2006 C - I R M EP]; A61K-009/22 [2006 C - I R M US];
  A61K-031/4468 [2006 C - I R M EP]; A61K-031/4523 [2006 C - I R M EP];
  A61K-047/10 [2006 C - I R M EP]; A61K-047/14 [2006 C - I R M EP];
  A61K-047/26 [2006 C - I R M EP]
EPO ECLA Class :
  A61K-009/00M5D
  A61K-031/4468
  A61K-031/4535
  A61K-047/10
  A61K-047/14
  A61K-047/26
:
  ORIGINAL (O) : 424422000; CROSS-REFERENCE (X) : 424423000 424424000
  424425000 424449000 424450000 424473000 424484000 514282000
  604890100 604891100 604892100
Document Type :
  Corresponding document
Citations :
  Cited by examiner
  -US6541021 [US6541021] 424422000
  Cited by applicant
  -US3141823 [US3141823]
  -US3760984 [US3760984]
  -US3916899 [US3916899]
  -US3923426 [US3923426]
  -US3987790 [US3987790]

-US3995631 [US3995631]
-US3998834 [US3998834]
-US4016880 [US4016880]
-US4036228 [US4036228]
-US4111202 [US4111202]
-US4111203 [US4111203]
-US4167574 [US4167574]
-US4203440 [US4203440]
-US4203442 [US4203442]
-US4210139 [US4210139]
-US4327725 [US4327725]
-US4360019 [US4360019]
-US4487603 [US4487603]
-US4576951 [US4576951]
-US4582835 [US4582835]
-US4588580 [US4588580]
-US4627850 [US4627850]
-US4681560 [US4681560]
-US4692147 [US4692147]
-US4725852 [US4725852]
-US4769372 [US4769372]
-US4781924 [US4781924]
-US4865845 [US4865845]
-US5057318 [US5057318]
-US5059423 [US5059423]
-US5112614 [US5112614]
-US5137727 [US5137727]
-US5180716 [US5180716]
-US5187177 [US5187177]
-US5234692 [US5234692]
-US5234693 [US5234693]
-US5346903 [US5346903]
-US5356635 [US5356635]
-US5451408 [US5451408]
-US5472943 [US5472943]
-US5486362 [US5486362]
-US5487739 [US5487739]
-US5512578 [US5512578]
-US5580876 [US5580876]
-US5633000 [US5633000]
-US5660854 [US5660854]
-US5672167 [US5672167]
-US5729396 [US5729396]
-US5747058 [US5747058]
-US5767125 [US5767125]
-US5798114 [US5798114]
-US5858388 [US5858388]
-US5980927 [US5980927]
-US5985305 [US5985305]
-USRE36547 [USRE36547]
-US6096756 [US6096756]
-US6203813 [US6203813]
-US6245351 [US6245351]
-US6436091 [US6436091]
-WO9727840 [WO9727840]
-WO9749391 [WO9749391]
-WO9851246 [WO9851246]
-WO9936071 [WO9936071]
Cited by applicant
-Ahmedzai (1997), "New approaches to pain control in patients with cancer." Eur. J. Cancer, 33(6):S8-S14.
- Anderson et al.. (1998), "Alternate routes of opioid administration in palliative care: pharmacologic and clinical concerns." J. Pharmaceut.

Care Pain Sympt. Control, 6:5-21.
- Bansinath, et al.. (1989). "Hyperglycemia does not modify the pupillary effects of mu and kappa opiate Agonists in mice" J. Ocular Pharmacology, vol. 5(1): 33-43.
- Bruera et al.. (1987). "Use of the subcutaneous route of the administration of narcotics in patients with cancer pain" Cancer, vol. 62(2): 407-411.
- Cherny et al.. 1995). "Opioid pharmacotherapy in the management of cancer pain" Cancer, vol. 76(7): 1283-1293.
- Clotz et al.. (1991). "Clinical uses of fentanyl, sufentanil, and alfentanil" Clinical Pharmacy, vol. 10: 581-593.
- Coda et al.. (1997). "Comparative efficacy of patient-controlled administration of morphine, hydromorphone, or sufentanil for the treatment of oral mucositis pain following bone marrow transplantation" Pain, vol. 72: 333-346.
- Coyle et al.. (1994), "Subcutaneous opioid infusions at home." Oncology, 8:21-27.
- Crane (1994). "Intermittent subcutaneous infusion of opioids in hospice home care: An affective, economical, manageable option" Am. J. Hospice & Palliative Care, vol. Jan./Feb.: 8-12.
- Dhasmana et al.. (1987). "Gastrointestinal transit following inthrathecal or subcutaneous narcotic analgesics" Arch. Int. Pharmacodyn., vol. 286: 152-161.
- Fine (1997), "Fentanyl in the treatment of cancer pain." Sem. Oncol., 24(16):S16-S27.
- Finley (1990), "Pain management with spinally administered opioids." Am. J. Hosp. Pharm., 47(1):S14-S17.
- Fuginaga et al.. (1988). "Reproductive and teratogenic effects of sufentanil and alfentanil in Sprague-Dawley rate" Anesth Analg, vol. 67: 166-169.
- Geller et al.. (1993). "A randomized double-blind comparison of epidural sufentanil versus intravenous sufentanil or epidural fentanyl analgesia after major abdominal surgery" Anesth Analg, vol. 76: 1243-1250.
- Jeal et al.. (1997), "Transdermal fentanyl. A review of its pharmacologic properties and therapeutic efficacy in pain control." Drugs, 53:109-138.
- Kerr et al.. (1988), "Continuous narcotic infusion with patient-controlled analgesia for chronic cancer pain in outpatients." Ann. Intern. Med., 108:554-557.
- Kingery (1997), "A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes." Pain, 73:123-139.
- Leelanuntakit (1996). "Management of cancer-related pain with transdermal fentnyl" J. Med. Assoc. Thai, vol. 79(6): 341-346.
- Martin et al.. (1983), "Epidural and intrathecal narcotics." Can. Anaesth. Soc. J., 30:662-673.
- Moulin et al.. (1992). "Subcutaneous narcotic infusions for cancer pain: treatment outcome and guidelines for use" Can. Med. Assoc. J., vol. 146:(6): 891-897.
- Mucha et al.. (1990). "Parker and Radow test of drug withdrawal aversion: Opposite effect in rats chronically infused with sufentanil or amphetamine" Pharmacology Biochem. & Behavior, vol. 35: 219-224.
- Paix et al.. (1995). "Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain mangement" Pain, vol. 3:263-269.
- Satterlee (1991). "Criteria for use of fentanyl citrate, sufentanil citrate, and alfentanil hydrochloridea" Clinical Pharmacy, vol. 10: 635-637.
- Shaw (1993), "Treatment of intractable cancer pain by electronically controlled parenteral infusion of analgesic drugs." Cancer, 72:3416-3425.
- Skaer (1993), "Management of pain in the cancer patient." Clin. Ther.,

15:638-649.
- Slattery et al.. (1985), "Newer methods of delivery of opiates for relief of pain." Drugs, 30:539-551.
- Sj/ogren et al.. (1994). "Disappearace of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists" Pain, vol. 59: 313-316.
- Taverne et al.. (1992). "Comparative absorption and distribution pharmacokinetics of intravenous and epidural sufentanil for major abdomincal surgery" Clin. Pharmacokinet., vol. 23(3): 231-237.
- Van den Hoogen et .. (1987). "Epidural and subcutaneous morphine, meperidine (pethidine), fentanyl and sufentanil in the rat: Analgesia and other in vivo pharmacologic effects" Anesthesiology, vol. 66: 186-194.
- Van den Hoogen et al.. (1988). "Respiratory effects of epidural and subcutaneous morphine, meperidine (pethidine), fentanyl and sufentanil in the rat" Anesth Analg, vol. 67:1071-1078.
- Vertafridda et al.. (1987), "Intraspinal morphine for cancer pain." Acta Anaesthesiol Scand., 31(85):47-53.
- Wagner et al.. (1997). "Pharmacokinetics and pharmacodynamics of sedatives and analgescics in the treatment of agitated critically ill patients" Clin. Pharmacokinet, vol. 33(6): 426-453.
- Willens et al.. (1993). "Pharmacodynamics, pharmacokinetics, and clinical uses of fentanyl, sufentanil, and alfentanil" Heart & Lung, vol. 22(3): 239-251.
- Zeiler et al.. (1991). "Kontinuierliche peridurale sufentanil-applikation zur postoperativen analgesie" Anaesthesist, vol. 40: 543-548.

Publication Stage :
(Al) Utility Patent Application published on or after January 2, 2001

Publication Stage 2 :
(B2) U.S. Patent (with pre-grant pub.) after Jan. 2, 2001

Abstract :
The invention features devices and methods for the systemic delivery of fentanyl or a fentanyl congener (e.g., sufentanil) to treat pain. In the present invention, a drug formulation comprising fentanyl or a fentanyl congener is stored within a drug delivery device (e.g., contained in a reservoir or impregnated within a matrix within the controlled drug delivery device). The drug formulation comprises an amount of drug sufficient for treatment and is stable at body temperatures (i.e., no unacceptable degradation) for the entire pre-selected treatment period. The drug delivery devices store the drug formulation safely (e.g., without dose dumping), provide sufficient protection from bodily processes to prevent unacceptable degradation of the formulation, and release the drug formulation in a controlled fashion at a therapeutically effective rate to treat pain. In use, the drug delivery device is implanted in the subject's body at an implantation site, and the drug formulation is released from the drug delivery device to a delivery site. The delivery site may be the same as, near, or distant from the implantation site. Once released at the delivery site, the drug formulation enters the systemic circulation and is transported to the site of action in the body to modulate the pain response (e.g., the brain or other pain sensory location).

Update Code :
2003-49

Search statement 2

Query/Command : st

```
Session finished: 09 JUN 2008 Time 20:18:54

LGST         - Time in minutes :   0,06
The cost estimation below is based on Questel's
standard price list
                              Estimated cost :    0.07 USD
Cost estimated for the last database search :    0.07 USD
Estimated total session cost                :    1.75 USD

CRXX         - Time in minutes :   0,06
The cost estimation below is based on Questel's
standard price list
                              Estimated cost :    0.12 USD
Cost estimated for the last database search :    0.12 USD
Estimated total session cost                :    1.87 USD

LITA         - Time in minutes :   0,12
The cost estimation below is based on Questel's
standard price list
                              Estimated cost :    0.36 USD
Cost estimated for the last database search :    0.36 USD
Estimated total session cost                :    2.23 USD

PLUSPAT      - Time in minutes :   0,32
The cost estimation below is based on Questel's
standard price list
                              Estimated cost :    0.98 USD
Records displayed and billed   :      1
                              Estimated cost :    1.70 USD
Cost estimated for the last database search :    2.68 USD
Estimated total session cost                :    4.91 USD

Your session will be retained for 6 hours.

QUESTEL.ORBIT thanks you. Hope to hear from you again soon.
?
```